BioSpace News Archive

Rakuten Medical, Inc., a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.

Strados Labs, a medical technology company harnessing the power of smart sensors, machine learning and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases, announced its pre-series A round of funding at $4.5M.

Each year The National Kidney Foundation considers the work of hundreds of specialists in the field of Nephrology and selects among them those who most exemplify the relentless efforts of NKF to enhance the lives of patients through action, education, and accelerating change.

Boston Children’s Hospital and PM Pediatrics are now working together to provide premier urgent care for children and young adults in the Boston area.

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, reported it has filed for a utility patent for its multi-parameter, noninvasive sepsis monitor.

Global professional services firm ZS has been selected by leading biopharmaceutical company Bristol Myers Squibb (BMS) (NYSE: BMY) to support its worldwide commercial analytics organization.

Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, announced the appointment of Laurence Reid, Ph.D. to its board of directors.

DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Chief Executive Officer and Chairman Flagg Flanagan will present at the 40th Annual J.P. Morgan Healthcare Conference.

Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced the appointment of Jenny Gizzi to Chief People Officer, effective immediately.

Stryker announced that it will host a conference call on Thursday, January 27, 2022 at 4:30 p.m., Eastern Time, to discuss the Company’s operating results for the quarter ended December 31, 2021 and provide an operational update.